Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK.
BACKGROUND AND AIMS
We examined HbA1c and cardiovascular risk factors with a median follow-up of 44 months therapy with dapagliflozin.


METHODS
We undertook a clinical practice evaluation of 101 patients attending our clinic.


RESULTS
Dapagliflozin resulted in a significant reduction in HbA1c 82.6 ± 15.7 v 68.7 ± 17.8 mmol/mol.


CONCLUSION
Dapagliflozin maintains glycaemic control along with sustained improvements in weight and no decline in renal function.
['Shrikrishnapalasuriyar|Natasha|N|', 'Shaikh|Ayesha|A|', 'Ruslan|Aliya Mohd|AM|', 'Sharaf|Giselle|G|', 'Udiawar|Maneesh|M|', 'Price|David E|DE|', 'Stephens|Jeffrey W|JW|']
D000368:Aged D001559:Benzhydryl Compounds D003924:Diabetes Mellitus, Type 2 D005260:Female D005500:Follow-Up Studies D005960:Glucosides D006442:Glycated Hemoglobin A D000085002:Glycemic Control D006801:Humans D007004:Hypoglycemic Agents D008297:Male D008875:Middle Aged D063127:Secondary Care D016896:Treatment Outcome D006113:United Kingdom D015431:Weight Loss
Dapagliflozin HbA1c Cardiovascular SGLT2 inhibitor